#United States #New York #Class Action #Pomerantz Law #Galectin Therapeutics

Pomerantz Law Firm Launches Investigation into Galectin Therapeutics Inc.

Pomerantz LLP, a leading law firm known for its expertise in corporate and securities litigation, has initiated an investigation into potential claims on behalf of investors of Galectin Therapeutics Inc. (NASDAQ: GALT). The inquiry focuses on accusations suggesting that certain officers and directors of Galectin may have participated in securities fraud or engaged in other unlawful business practices, raising concerns among shareholders.

On December 19, 2025, Galectin Therapeutics announced that the U.S. Food and Drug Administration (FDA) had responded to the company's previous request for a Type C meeting, originally aimed at discussing its investigational drug, belapectin. This response was not delivered in the form of a meeting, as the FDA converted the request into a written communication. Although Galectin indicated it was aligned with the FDA regarding the patient population for a potential registration trial, significant elements of the trial design remain unresolved.

In market reaction to this news, Galectin's share price plummeted by $1.78, equating to a staggering decrease of 28.9%, closing at $4.38 per share on the day of the announcement. The sharp decline in stock value has sparked alarm among investors, prompting the Pomerantz Law Firm's investigation.

The Firm's Background

Founded by Abraham L. Pomerantz, a highly revered figure within the class action bar, Pomerantz LLP has a track record that spans over 85 years. The firm has earned recognition for its successful representation of clients in cases involving securities fraud, breaches of fiduciary duty, and other corporate malfeasance. Pomerantz has secured numerous multimillion-dollar settlements for victims of investor fraud and has a strong presence in key markets such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.

This current investigation underscores the firm’s continued commitment to defending the interests of shareholders and navigating the complex landscape of securities litigation.

How to Get Involved

Investors who believe they may have suffered losses due to their investment in Galectin Therapeutics are encouraged to reach out to Pomerantz attorney Danielle Peyton directly via email at [email protected] or by phone at 646-581-9980, ext. 7980. Affected shareholders can seek to join the class action by contacting the firm or through their website, where additional resources and information are available.

Conclusion

As the investigation unfolds, it highlights the critical need for transparency and accountability within publicly traded companies, especially in the volatile biotech sector. Investors in Galectin Therapeutics are advised to remain informed and vigilant as developments occur regarding this inquiry. The outcome may have substantial implications for the company and for those who have invested in its future.

For more information about the ongoing investigation and how to participate, please visit Pomerantz LLP's website.